Drug Profile
Salinomycin nanoparticle - Tharimmune
Alternative Names: HSB-1216Latest Information Update: 28 Oct 2023
Price :
$50
*
At a glance
- Originator Hillstream BioPharma
- Developer Dana-Farber Cancer Institute; Indian Institutes of Technology; Tharimmune
- Class Antibacterials; Antineoplastics; Antiprotozoals; Butyric acids; Polyketides; Small molecules
- Mechanism of Action Apoprotein stimulants; Apoptosis stimulants; Ferroptosis stimulants; Neoplastic stem cell inhibitors; Stem cell inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Clinical Phase Unknown Carcinoma; Triple negative breast cancer
- Preclinical Acute myeloid leukaemia; Non-small cell lung cancer
- No development reported Small cell lung cancer
Most Recent Events
- 28 Oct 2023 No recent reports of development identified for preclinical development in Small-cell-lung-cancer in USA (Intratumoural, Injection)
- 27 Apr 2023 Hillstream Biopharma plans a clinical trial for Cancer in second half of 2023
- 13 Apr 2023 Hillstream Biopharma intends to submit IND application to the US FDA for Cancer in second half of 2023